HomeTagsImmunotherapy option

immunotherapy option

Merck’s KEYTRUDA Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer

Merck, known as MSD outside of the United States and Canada, announced results from the Phase 3 KEYNOTE-966 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy,...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics